Home Sectors Health
Russia announces that it has developed a new cancer vaccine, which will be distributed free of charge in 2025
Russia announces that it has developed a new cancer vaccine, which will be distributed free of charge in 2025.
The Russian Ministry of Health has announced that it has developed a cancer vaccine, which will be distributed free of charge to patients in early 2025.
The vaccine not only slows down the progression of the tumor, but also reduces the size of the tumor by 75-80%.
Andrey Kaprin, director of the Medical Research Center of Radiology at the Russian Ministry of Health, confirmed that the cancer vaccine will be launched in early 2025.
Unlike preventive vaccines, which aim to prevent the development of tumors in healthy individuals, this vaccine aims to treat existing cases of cancer.
Russian government scientists have suggested that, like cancer treatments developed in Western countries, the vaccine could be personalized for each patient. This personalized approach aims to tailor the vaccine to the specific type of cancer and the individual characteristics of each patient.
A trip through Quang Binh to breathtaking movie locations
Vaccine details unclear
While the announcement has caused excitement, many details remain unclear.
It is still not clear what types of cancer the vaccine is designed to treat, how effective it will be or how the Russian government plans to use it. The name of the vaccine has not yet been disclosed.
Alexander Gintsburg's views on vaccination
Alexander Gintsburg, director of the Gamaleya research center in Russia, emphasized: "This is not a universal vaccine. "It is a personalized vaccine, not only for each type of cancer, but also for any type of cancer. It is a therapeutic vaccine and does not protect against infectious diseases. It treats people suffering from oncological diseases. »
The news follows after this announcement
How the vaccine works
Gintsburg also explained that this drug or vaccine is a bit "vulgar", figuratively speaking. It directs the patient's immune system against malignant cells, because this vaccine carries in its composition the changes that are characteristic at the genetic level of tumors.
"As a result, the patient's immune system recognizes these cells, which carry cancer markers, and begins to destroy them with cytotoxic lymphocytes - special immune cells that essentially devour cells carrying tumor markers. "So that's the point of this vaccine," he explained.
Collaboration with leading cancer centers
At the Gamaleya Institute, Gintsburg and his team collaborate with colleagues from two leading cancer centers: the Herzen Center, headed by Professor Caprin, and the Blokken Center, headed by Academician Stilidi. They also work with young colleagues from the Serious Center.
"A system has been created that allows us to genetically transfer the necessary genetic sequences into our eukaryotic cells," Gintsburg explained. These methods and technologies are fully covered by national patents, which allows us to use them widely and openly to create medicines. »
Focus on melanoma vaccine prototypes. The first goal is to focus on vaccine prototypes created against melanoma, the most malignant and serious oncological disease.
Gintsburg explained that the mouse melanoma model shows that three variants of vaccines created with these technologies protect these animals from immediate death.
Global efforts in personalized cancer vaccines
Meanwhile, other countries are also working on their own personalized cancer vaccines, highlighting the growing global interest in this promising area of cancer treatment.
[attachment deleted by admin]